Best Peptides for Energy: Evidence-Based Rankings
Introduction: Why Peptides Stand Out for Energy Enhancement
Energy production sits at the intersection of metabolism, mitochondrial function, and hormonal signaling. While conventional supplements like caffeine or B-vitamins work through single mechanisms—primarily central nervous system stimulation or cofactor provision—peptides operate as cellular signaling molecules that can upregulate multiple pathways simultaneously.
Peptides work at the receptor level to enhance mitochondrial ATP production, improve substrate utilization efficiency, reduce fatigue-associated inflammatory markers, and optimize metabolic rate. This multi-system approach explains why evidence-based peptides often produce more sustained energy improvements than stimulant-based supplements that fade as the body develops tolerance.
The peptides ranked here have been selected based on rigorous evidence criteria: only those with Tier 4 evidence (high confidence from multiple human RCTs) or Tier 3 evidence (probable efficacy from smaller human studies) for energy-specific outcomes are included. Each has demonstrated measurable improvements in markers like energy expenditure, exercise capacity, fatigue scales, or metabolic efficiency in human studies.
Ranking: Best Peptides for Energy
1. GLP-1 (Glucagon-Like Peptide-1) — Tier 4 Evidence
What It Is
GLP-1 is a hormone peptide that regulates glucose metabolism, appetite, and energy expenditure. GLP-1 receptor agonists like liraglutide and exenatide are the most studied peptides for metabolic enhancement and have moved from diabetes management into broader metabolic optimization.
Evidence for Energy
GLP-1 achieves Tier 4 evidence status—the highest confidence level—because multiple human randomized controlled trials and longitudinal studies consistently demonstrate improvements in energy expenditure and mitochondrial function.
Key findings include:
- Liraglutide RCT (n=49, 5 weeks): Increased 24-hour energy expenditure with improved glycemic control; fasting glucose reduced by 0.5–0.6 mmol/L versus placebo (P<0.0001).
- Longitudinal observational study (1 year): Both exenatide and liraglutide increased energy expenditure in obese type 2 diabetic patients, with effects sustained over 12 months.
The mechanism involves enhanced mitochondrial function and ATP production, though weight loss primarily results from appetite suppression rather than pure metabolic acceleration. The energy expenditure improvements are modest but consistent and clinically meaningful.
Dosing & Cost
- Dosing: 100–300 mcg once or twice daily (injection)
- Cost: $40–$120/month
Best For
Those seeking sustained metabolic enhancement with the strongest human evidence base. Particularly valuable for individuals with metabolic dysfunction or those managing weight while maintaining energy levels.
2. SS-31 (Elamipretide) — Tier 3 Evidence
What It Is
SS-31 (elamipretide) is a mitochondria-targeted peptide that crosses into mitochondria and stabilizes cardiolipin, a critical phospholipid in the inner mitochondrial membrane. This directly enhances energy production at the cellular level.
Evidence for Energy
SS-31 achieves Tier 3 evidence—probable efficacy—based on clinical trials showing substantial improvements in exercise capacity and fatigue in specific mitochondrial disease populations.
Key findings include:
- Barth syndrome (n=10, 168-week open-label extension): 96.1-meter cumulative improvement in 6-minute walk test distance, a standard measure of functional energy capacity. Benefits sustained throughout the study period.
- Primary mitochondrial myopathy with nDNA replisome variants (recent RCT): 25.2 ± 8.7 meter improvement on 6-minute walk test with elamipretide versus 2.0 ± 8.6 meters with placebo, trending toward statistical significance despite small sample size.
The evidence is robust for mitochondrial disease populations but remains limited in healthy individuals or broader fatigue contexts.
Dosing & Cost
- Dosing: 0.1–0.5 mg/kg or fixed 4–40 mg once daily (injection)
- Cost: $80–$400/month
Best For
Individuals with diagnosed mitochondrial dysfunction, chronic fatigue syndrome with mitochondrial markers, or those seeking cellular-level energy optimization. Less established for healthy populations seeking general energy enhancement.
3. ARA-290 (Cibinetide) — Tier 3 Evidence
What It Is
ARA-290 is an erythropoietin receptor agonist peptide that modulates innate immune responses and reduces neuroinflammation. It improves fatigue and exercise capacity by reducing inflammatory fatigue markers and supporting nerve fiber health.
Evidence for Energy
ARA-290 holds Tier 3 evidence based on three human RCTs in sarcoidosis patients with small fiber neuropathy, demonstrating consistent improvements in fatigue and exercise capacity, though effect sizes remain modest.
Key findings include:
- Fatigue Assessment Scale improvement (n=22, 4-week IV trial): Significant fatigue improvement in ARA-290 group; however, placebo also showed substantial improvement, limiting clarity on absolute effect size.
- 6-minute walk test increase (n=48, 28-day subcutaneous trial): Increased exercise capacity in sarcoidosis patients; corneal nerve fiber density also improved, suggesting reduced neuropathic contributions to fatigue.
Evidence is strongest in small fiber neuropathy and sarcoidosis contexts but lacks replication in healthy populations or other fatigue etiologies.
Dosing & Cost
- Dosing: 4 mg once daily (injection)
- Cost: $180–$480/month
Best For
Those with sarcoidosis, small fiber neuropathy-associated fatigue, or chronic inflammatory fatigue conditions. Less evidence supports use in primary fatigue or healthy energy optimization.
4. Ibutamoren (MK-677) — Tier 3 Evidence
What It Is
Ibutamoren is an orally-active growth hormone secretagogue that stimulates pituitary growth hormone and IGF-1 release. It increases fat-free mass and energy expenditure, supporting metabolic rate and muscle protein retention.
Evidence for Energy
Ibutamoren holds Tier 3 evidence—probable efficacy—based on two small human RCTs demonstrating meaningful improvements in body composition and nitrogen balance during energy deficit, though the mechanism isn't purely energy-based.
Key findings include:
- Nitrogen balance reversal during caloric restriction (n=8, human RCT): Nitrogen balance improved from −1.48 ± 0.21 g/day on placebo to +0.31 ± 0.21 g/day with 25 mg MK-677 daily (P<0.01). This indicates preserved or gained lean mass despite caloric restriction, supporting sustained metabolic activity.
- Fat-free mass increase (n=12 obese males, 8-week RCT): Significant increase in fat-free mass measured by dual-energy X-ray absorptiometry with 25 mg daily dosing (P<0.01).
Energy benefits are indirect—preserved lean mass supports higher basal metabolic rate—rather than direct energy expenditure increases.
Dosing & Cost
- Dosing: 10–25 mg once daily (oral)
- Cost: $30–$80/month
Best For
Those prioritizing lean mass preservation during caloric restriction or seeking metabolic support through enhanced body composition. The oral route increases convenience compared to injectable peptides.
5. Cortexin (Brain Peptide Complex) — Tier 3 Evidence
What It Is
Cortexin is a complex of neuropeptides and amino acids extracted from brain tissue, designed to support cognitive function and reduce central fatigue. It operates through multiple mechanisms including anti-inflammatory signaling and potential nootropic effects.
Evidence for Energy
Cortexin holds Tier 3 evidence based on multiple observational studies and one RCT demonstrating improvements in fatigue scales and cognitive function in post-COVID and chronic fatigue populations, though independent replication remains limited.
Key findings include:
- Post-COVID fatigue (n=979, observational): 10–20 mg IM for 10 days improved Multidimensional Fatigue Inventory (MFI-20) scores, Montreal Cognitive Assessment (MoCA) cognition measures, and reduced pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Gains maintained at 30-day follow-up.
- RCT evidence (n=150 post-COVID patients): Cortexin monotherapy improved MFI-20 fatigue scores and MoCA cognitive status; transcranial stimulation combined with Cortexin showed additional benefit.
Evidence is strongest in post-COVID and post-viral fatigue contexts but lacks validation in primary chronic fatigue or healthy populations.
Dosing & Cost
- Dosing: 10 mg once daily (injection)
- Cost: $40–$120/month
Best For
Those experiencing post-COVID or post-viral fatigue, chronic fatigue with cognitive dysfunction, or central nervous system-mediated fatigue. Less evidence supports use for primary energy optimization in healthy individuals.
6. Setmelanotide — Tier 3 Evidence
What It Is
Setmelanotide is a melanocortin 4 receptor (MC4R) agonist peptide that increases resting energy expenditure and shifts substrate utilization toward fat oxidation. It was developed for rare genetic obesity syndromes but has been studied for metabolic effects in broader populations.
Evidence for Energy
Setmelanotide holds Tier 3 evidence based on one small human RCT demonstrating modest increases in resting energy expenditure and favorable substrate utilization shifts, though the clinical significance remains debated.
Key findings include:
- Resting energy expenditure increase (n=12, 72-hour double-blind RCT): 6.4% increase in resting energy expenditure versus placebo (95% CI: 0.68–13.02%, absolute increase 111 kcal/24h, P=.03).
- Substrate utilization shift (same RCT): 23-hour nonexercise respiratory quotient lower during setmelanotide treatment (0.833 ± 0.021 vs 0.848 ± 0.022, P=.02), indicating increased fat oxidation preference.
The absolute energy increase (111 kcal/day) is modest and cost-prohibitive relative to benefit. Evidence is strongest in rare genetic obesity but weak for general energy optimization.
Dosing & Cost
- Dosing: 2–3 mg once daily (injection)
- Cost: $18,000–$25,000/month
Best For
Individuals with rare genetic obesity syndromes (POMC, PCSK1, LEPR mutations) where setmelanotide is FDA-approved. Not recommended for general energy optimization due to cost, modest effect size, and limited efficacy evidence in healthy populations.